Profile of vemurafenib-induced severe skin toxicities - PubMed (original) (raw)
doi: 10.1111/jdv.13443. Epub 2015 Nov 2.
Affiliations
- PMID: 26524690
- DOI: 10.1111/jdv.13443
Profile of vemurafenib-induced severe skin toxicities
L Peuvrel et al. J Eur Acad Dermatol Venereol. 2016 Feb.
Abstract
Background: Vemurafenib, a BRAF inhibitor, is commonly associated with skin toxicity. The impact of severe forms is unknown.
Objective: To determine the rate of permanent vemurafenib discontinuation due to grade 3-4 skin toxicity, features of these toxicities, their recurrence rate after a switch to dabrafenib and their impact on overall survival.
Methods: Retrospective cohort study of 131 patients treated with vemurafenib for melanoma between November 2010 and December 2014. Data on skin toxicities, the need for vemurafenib adjustment and the impact of switching to dabrafenib were collected. Regarding survival analysis, a conditional landmark analysis was performed to correct lead-time bias.
Results: Among the 131 vemurafenib-treated patients, 26% developed grade 3-4 skin toxicity. Forty-four percent of them permanently discontinued their treatment, mainly due to rash and classic skin adverse reactions (Steven-Johnson syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms). Conversely, photosensitivity and carcinomas rarely required treatment adjustment. Grade 3-4 rashes were associated with clinical or biological abnormalities in 94% of patients. Among the 10 patients who subsequently switched to dabrafenib, skin toxicity recurred only in one patient. Overall survival was significantly prolonged in case of severe skin toxicity emerging within the first 4 (P = 0.014) and 8 weeks (P = 0.038) on vemurafenib, with only a trend at 12 weeks (P = 0.052). Median overall survival was also prolonged in case of severe rash.
Conclusion: In this study, vemurafenib was continued in 56% of patients with grade 3-4 skin toxicity, which was associated with prolonged overall survival when emerging within the first 4 and 8 weeks of treatment. While developing severe skin adverse reactions permanently contraindicates vemurafenib use, other rashes should lead to retreatment attempts with dose reduction. In case of recurrence, dabrafenib seems to be an interesting option. For other skin toxicities, including photosensitivity and cutaneous carcinoma, treatment adjustment is usually not needed.
© 2015 European Academy of Dermatology and Venereology.
Similar articles
- [Successful drug desensitization after vemurafenib-induced rash].
Klossowski N, Kislat A, Homey B, Gerber PA, Meller S. Klossowski N, et al. Hautarzt. 2015 Apr;66(4):221-3. doi: 10.1007/s00105-015-3590-4. Hautarzt. 2015. PMID: 25698338 German. - Early-Onset Vemurafenib-Induced DRESS Syndrome.
Munch M, Peuvrel L, Brocard A, Saint Jean M, Khammari A, Dreno B, Quereux G. Munch M, et al. Dermatology. 2016;232(1):126-8. doi: 10.1159/000439272. Epub 2015 Sep 30. Dermatology. 2016. PMID: 26418832 - Drug safety evaluation of vemurafenib in the treatment of melanoma.
Tsai KY, Nowroozi S, Kim KB. Tsai KY, et al. Expert Opin Drug Saf. 2013 Sep;12(5):767-75. doi: 10.1517/14740338.2013.813017. Epub 2013 Jun 26. Expert Opin Drug Saf. 2013. PMID: 23800008 Review. - Cutaneous adverse events during vemurafenib therapy.
Chandrakumar SF, Yeung J. Chandrakumar SF, et al. J Cutan Med Surg. 2014 Jul-Aug;18(4):223-8. doi: 10.2310/7750.2013.13120. J Cutan Med Surg. 2014. PMID: 25008438 Review.
Cited by
- Valacyclovir as Etiology for Drug Reaction with Eosinophilia and Systemic Symptoms: A Case Report.
Downs D, Sivakolundu K, Lim N, Kandula M. Downs D, et al. J Community Hosp Intern Med Perspect. 2023 Nov 4;13(6):8-12. doi: 10.55729/2000-9666.1248. eCollection 2023. J Community Hosp Intern Med Perspect. 2023. PMID: 38596552 Free PMC article. - Diagnosis and Management of Dermatologic Adverse Events from Systemic Melanoma Therapies.
Fay CJ, Jakuboski S, Mclellan B, Allais BS, Semenov Y, Larocca CA, LeBoeuf NR. Fay CJ, et al. Am J Clin Dermatol. 2023 Sep;24(5):765-785. doi: 10.1007/s40257-023-00790-8. Epub 2023 Jul 3. Am J Clin Dermatol. 2023. PMID: 37395930 Free PMC article. Review. - Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Focus on the Pathophysiological and Diagnostic Role of Viruses.
Ramirez GA, Ripa M, Burastero S, Benanti G, Bagnasco D, Nannipieri S, Monardo R, Ponta G, Asperti C, Cilona MB, Castagna A, Dagna L, Yacoub MR. Ramirez GA, et al. Microorganisms. 2023 Jan 30;11(2):346. doi: 10.3390/microorganisms11020346. Microorganisms. 2023. PMID: 36838310 Free PMC article. Review. - Prolonged Complete Response With Combined Dabrafenib and Trametinib After BRAF Inhibitor Failure in BRAF-Mutant Glioblastoma.
Kushnirsky M, Feun LG, Gultekin SH, de la Fuente MI. Kushnirsky M, et al. JCO Precis Oncol. 2020 Feb 3;4:PO.19.00272. doi: 10.1200/PO.19.00272. eCollection 2020. JCO Precis Oncol. 2020. PMID: 32923904 Free PMC article. No abstract available. - Cutaneous Adverse Events of Anti-PD-1 Therapy and BRAF Inhibitors.
Gnanendran SS, Turner LM, Miller JA, Hwang SJE, Miller AC. Gnanendran SS, et al. Curr Treat Options Oncol. 2020 Mar 19;21(4):29. doi: 10.1007/s11864-020-0721-7. Curr Treat Options Oncol. 2020. PMID: 32193712 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials